We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva...
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F ») Daix (France), Long Island City (New York, United States), le 3 avril...
Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur Daix (France), Long Island City (New York, États-Unis), le 28 mars 2024 – Inventiva (Euronext Paris et Nasdaq : IVA...
Inventiva announces the nomination of Andre Turenne as Director Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the...
Inventiva publie ses résultats annuels 2023 Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, en hausse de 43,4 % par rapport à 12,2 millions d’euros en 2022Trésorerie et...
Inventiva reports its 2023 full-year results Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million...
Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023 Daix (France), Long Island City (New York, Etats-Unis), le 22 mars 2024 – Inventiva (Euronext...
Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de...
Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the...
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed Inventiva has lifted the voluntary pause on screening and randomization...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.16 | -5.06329113924 | 3.16 | 3.2 | 2.945 | 16961 | 3.09072014 | DE |
4 | -0.34 | -10.1796407186 | 3.34 | 3.6 | 2.945 | 29423 | 3.31708692 | DE |
12 | -0.475 | -13.6690647482 | 3.475 | 4.3 | 2.8 | 69689 | 3.34415561 | DE |
26 | -0.36 | -10.7142857143 | 3.36 | 4.44 | 2.8 | 55697 | 3.54259779 | DE |
52 | 0.8 | 36.3636363636 | 2.2 | 4.84 | 1.88 | 94042 | 3.50423061 | DE |
156 | -7.8 | -72.2222222222 | 10.8 | 13.18 | 1.88 | 53289 | 5.18880987 | DE |
260 | 0.33 | 12.3595505618 | 2.67 | 16.3 | 1.54 | 65374 | 6.9569605 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions